Cell Therapy Facility Readiness and CQV Remediation
CLIENT OVERVIEW
A clinical stage cell therapy company preparing to expand its manufacturing capacity to support Phase Two and Phase Three material.
CLIENT CHALLENGE
The organization was bringing new cleanrooms, single use bioreactors, and supporting utilities online. Internal CQV documentation was inconsistent, several systems required re-qualification, and inspection readiness gaps had been identified. Internal staffing constraints created additional risk to timelines.
PIONEER ENGAGEMENT
Comprehensive GMP facility assessment focused on aseptic processing, environmental control, chain of identity, and cell therapy specific risks
Development of a structured CQV Master Plan and protocol suite
On-site commissioning and qualification execution for cleanrooms, HVAC, closed systems, autoclaves, and cryogenic storage
Remediation of incomplete validation reports
Alignment of validation strategy with ATMP expectations
Coaching internal staff to build a sustainable long-term validation program
KEY DELIVERABLES
CQV Master Plan
Protocol suite
Remediation tracker
Facility readiness risk assessment
Inspection readiness package
OUTCOME
The site achieved facility readiness ahead of schedule with complete and compliant CQV documentation, enabling on-time clinical manufacturing.
